Reference health
HIV-1 Vaccine-Induced C1 and V2 Env-Specific Antibodies Synergize for Increased Antiviral Activities
37/37 checkable references clean · checked 2026-07-26
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
1 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 37 checked references that resolve
resolves10.1056/NEJMoa0908492
Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand
resolves10.1038/nature11519
Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2
resolves10.1016/j.immuni.2012.11.011
Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2
resolves10.1128/JVI.01023-12
Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies from an HIV-1 Vaccine Efficacy Trial Target Multiple Epitopes and Preferentially Use the VH1 Gene Family
resolves10.1073/pnas.1301456110
Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG
resolves10.1016/j.virol.2011.09.019
Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitors
resolves10.1089/aid.2008.0129
<i>Short Communication: In Vitro</i>
Synergy between Peptides or Neutralizing Antibodies Targeting the N- and C-Terminal Heptad Repeats of HIV Type 1 gp41
resolves10.1128/JVI.75.24.12198-12208.2001
Neutralization Synergy of Human Immunodeficiency Virus Type 1 Primary Isolates by Cocktails of Broadly Neutralizing Antibodies
resolves10.1128/JVI.75.19.9177-9186.2001
Additive Effects Characterize the Interaction of Antibodies Involved in Neutralization of the Primary Dualtropic Human Immunodeficiency Virus Type 1 Isolate 89.6
resolves10.1128/jvi.70.7.4466-4473.1996
Synergistic neutralization of human immunodeficiency virus type 1 by a chimpanzee monoclonal antibody against the V2 domain of gp120 in combination with monoclonal antibodies against the V3 loop and the CD4-binding site
resolves10.1128/jvi.71.10.7198-7206.1997
Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12
resolves10.1128/jvi.68.6.4001-4008.1994
Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies
resolves10.1089/aid.1992.8.425
Synergy Between Human Monoclonal Antibodies to HIV Extends Their Effective Biologic Activity Against Homologous and Divergent Strains
resolves10.1089/aid.1992.8.461
Synergistic Neutralization of HIV-1 by Human Monoclonal Antibodies Against the V3 Loop and the CD4-Binding Site of gp120
resolves10.1086/422258
Safety and Immunogenicity of an HIV Subtype B and E Prime‐Boost Vaccine Combination in HIV‐Negative Thai Adults
resolves10.1128/JVI.05045-11
Analysis of a Clonal Lineage of HIV-1 Envelope V2/V3 Conformational Epitope-Specific Broadly Neutralizing Antibodies and Their Inferred Unmutated Common Ancestors
resolves10.1128/JVI.00171-11
An HIV-1 gp120 Envelope Human Monoclonal Antibody That Recognizes a C1 Conformational Epitope Mediates Potent Antibody-Dependent Cellular Cytotoxicity (ADCC) Activity and Defines a Common ADCC Epitope in Human HIV-1 Serum
resolves10.2174/1570162X113116660059
Epitope Specificity of Human Immunodeficiency Virus-1 Antibody Dependent Cellular Cytotoxicity [ADCC] Responses
resolves10.4049/jimmunol.178.7.4424
The Role of Antibody Polyspecificity and Lipid Reactivity in Binding of Broadly Neutralizing Anti-HIV-1 Envelope Human Monoclonal Antibodies 2F5 and 4E10 to Glycoprotein 41 Membrane Proximal Envelope Epitopes
resolves10.1128/JVI.00927-07
Human Immunodeficiency Virus Type 1 gp41 Antibodies That Mask Membrane Proximal Region Epitopes: Antibody Binding Kinetics, Induction, and Potential for Regulation in Acute Infection
resolves10.1016/j.virol.2010.08.028
Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC
resolves10.1128/jvi.59.2.284-291.1986
Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone
resolves10.1128/JVI.79.16.10108-10125.2005
Human Immunodeficiency Virus Type 1<i>env</i>Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies
resolves10.1128/JVI.05601-11
Dynamic Antibody Specificities and Virion Concentrations in Circulating Immune Complexes in Acute to Chronic HIV-1 Infection
resolves10.1128/JVI.02737-12
Infectious Virion Capture by HIV-1 gp120-Specific IgG from RV144 Vaccinees
resolves10.1128/JVI.03765-13
Capacity for Infectious HIV-1 Virion Capture Differs by Envelope Antibody Specificity
resolves10.1007/978-1-59745-170-3_26
Measuring HIV Neutralization in a Luciferase Reporter Gene Assay
resolves10.1128/JVI.73.11.8966-8974.1999
A Cell Line-Based Neutralization Assay for Primary Human Immunodeficiency Virus Type 1 Isolates That Use either the CCR5 or the CXCR4 Coreceptor
resolves10.1182/blood.V94.12.4220.424k08_4220_4232
Variant Genotypes of the Low-Affinity Fcγ Receptors in Two Control Populations and a Review of Low-Affinity Fcγ Receptor Polymorphisms in Control and Disease Populations
resolves10.1016/0065-2571(84)90007-4
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors
resolves10.1089/aid.2012.0103
The Thai Phase III HIV Type 1 Vaccine Trial (RV144) Regimen Induces Antibodies That Target Conserved Regions Within the V2 Loop of gp120
resolves10.1128/jvi.68.12.8312-8320.1994
Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1
resolves10.1089/aid.1995.11.1095
Functional Activities of 20 Human Immunodeficiency Virus Type 1 (HIV-1)-Specific Human Monoclonal Antibodies
resolves10.1128/JVI.00287-12
Antibody-Dependent Cellular Cytotoxicity against Primary HIV-Infected CD4<sup>+</sup>T Cells Is Directly Associated with the Magnitude of Surface IgG Binding
resolves10.4049/jimmunol.1200501
Impact of Immune Complex Size and Glycosylation on IgG Binding to Human FcγRs
The 1 reference without a DOI — listed, not checked
no DOI — not checkedXuWSmith-FranklinBALiPLWoodCHeJDuQBhatGJKankasaCKatingerHCavaciniLAPosnerMRBurtonDRChouTCRuprechtRM. 2001. Potent neutralization of primary human immunodeficiency virus clade C isolates with a synergistic combination of human monoclonal antibodies raised against clade B. J. Hum. Virol. 4:55–61.
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-26 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1128/jvi.00156-14"><img src="https://citestamp.com/citestamped/10.1128/jvi.00156-14/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1128/jvi.00156-14)